← Back to Clinical Trials
Recruiting NCT06797037

NCT06797037 Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06797037
Status Recruiting
Phase
Sponsor Institut Claudius Regaud
Condition Solid Cancer
Study Type INTERVENTIONAL
Enrollment 33 participants
Start Date 2025-05-19
Primary Completion 2027-05-19

Trial Parameters

Condition Solid Cancer
Sponsor Institut Claudius Regaud
Study Type INTERVENTIONAL
Phase N/A
Enrollment 33
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-05-19
Completion 2027-05-19
Interventions
Decentralised Pathway Coordinated by the Advanced Practice Nurse

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is an open-label, single-centre, category 2 "Jardé Law" proof-of-concept study designed to demonstrate the feasibility of a decentralised care pathway for patients with cancer or haematological malignancies receiving oral treatment. The study will be conducted on a population of 33 patients. In current practice, patients with certain solid cancers or haematological malignancies may be prescribed oral chemotherapy on a retroceded basis. In these cases, the oncologist (coordinating investigator) sees the patient for a consultation every 3 cycles to prescribe/renew the treatment for approximately 3 months. Every month, the patient returns to the centre to have the treatment dispensed by the hospital pharmacy. No medical consultation is associated with this visit. In this study, it is proposed to decentralise the delivery of treatment to these patients by introducing two visits to the patient's home by a service-providing nurse. The decentralised patient pathway will be organised and monitored by the Advanced Practice Nurse (APN) at the investigating centre, who will be responsible in particular for coordination with the service-providing nurse and the hospital pharmacy.

Eligibility Criteria

Inclusion Criteria: 1. Patient over 18. 2. A patient with solid cancer or haematological malignancy receiving oral retroceded therapy as part of standard management. 3. Patient with a performance index (ECOG): 0-2. 4. Patient contactable by telephone for follow-up by the Advanced Practice Nurse. 5. Patient willing to make two home visits within 6 months of inclusion. Exclusion Criteria: 1. Pregnant or breast-feeding patient. 2. Any psychological, family, geographical or social condition which, in the judgement of the oncologist, could potentially prevent the collection of informed consent or hinder compliance with the study protocol. 3. Patients deprived of their liberty by administrative or legal decision, or patients under guardianship.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology